# GLP-1 Geographic Expansion Strategy - Multi-Skill Integration Scenario

## Overview

**High-value demonstration scenario** combining 7 skills across 6 MCP servers to answer a real $10B+ strategic question: "Which countries should Novo Nordisk/Eli Lilly launch GLP-1 drugs next?"

**Status:** Design complete, ready for implementation
**Value:** $10B+ decision support
**Timeliness:** EXTREME - GLP-1s are hottest pharma story in 2024
**Complexity:** High - integrates epidemiology, economics, competition, financials
**Business Impact:** Board-ready strategic recommendations

---

## The Business Problem

### Context

- **Companies:** Novo Nordisk (Ozempic, Wegovy), Eli Lilly (Mounjaro, Zepbound)
- **Market:** GLP-1 drugs for diabetes/obesity - $100B+ peak sales potential
- **Challenge:** Demand massively exceeds supply (years-long waitlists)
- **Decision:** Manufacturing capacity expanding but limited - must prioritize which countries to launch next

### Real-World Urgency

- Novo Nordisk is now Europe's most valuable company (surpassed LVMH in 2024)
- Stock performance: NVO +60% YTD, LLY +55% YTD
- Supply constraints forcing geographic prioritization decisions NOW
- Each country launch requires:
  - Regulatory approval (12-24 months)
  - Manufacturing allocation (decided NOW)
  - Commercial infrastructure ($50M+ per country)
  - Pricing/reimbursement negotiations

### The Question

**"We can add capacity for 5 new countries in 2025. Which 5?"**

This requires balancing:
- Disease burden (where is need highest?)
- Market size (population √ó prevalence √ó pricing power)
- Competition (who else is entering?)
- Regulatory (approval timelines, pricing restrictions)
- Commercial readiness (healthcare infrastructure)

---

## Why This Scenario Is Brilliant

### 1. Extreme Timeliness ‚ö°Ô∏è
- GLP-1s are THE hottest pharmaceutical story (cultural zeitgeist)
- Novo Nordisk stock up 60% in 2024
- Supply shortage creating urgent prioritization decisions
- Perfect timing for demonstrating strategic value

### 2. Massive Commercial Value üí∞
- Informs $10B+ market expansion decisions
- Determines manufacturing/supply chain investments
- Guides commercial team hiring and infrastructure
- Directly impacts stock price and shareholder value

### 3. Genuinely Solves a Real Problem üéØ
- Pharma companies are literally asking this question NOW
- No single data source provides the answer
- Requires integrating disparate data: epidemiology + economics + competition
- Creates insights impossible to achieve with siloed analysis

### 4. Demonstrates Platform Power üî•
- Combines 7 skills across 6 different MCP servers
- Integrates 5 distinct analytical layers
- Shows how data integration creates insights > sum of parts
- Proves strategic value, not just tactical data retrieval

### 5. Creates Actionable Outputs üìä
- Not descriptive ("here's data") but prescriptive ("do this")
- Produces prioritized country list with financial models
- Board-ready recommendations with ROI calculations
- Directly feeds strategic planning and board presentations

---

## Skills Orchestration

### Skills Required (7)

| Skill | MCP Server | Purpose | Data Output |
|-------|------------|---------|-------------|
| `get_disease_burden_per_capita` | who_mcp | Diabetes/obesity prevalence | 50+ countries with disease burden |
| `search_indicators` + `get_observations` | datacommons_mcp | Demographics & economics | Population, GDP, healthcare spend |
| `get_glp1_diabetes_drugs` | fda_mcp | Competitive drugs | 8 approved GLP-1 drugs |
| `get_clinical_trials` | ct_gov_mcp | Pipeline by geography | 500+ trials with location data |
| `get_company_segment_geographic_financials` | sec_mcp | Current company performance | Revenue by geography |
| `get_pharma_company_stock_data` | financials_mcp | Market sentiment | Stock performance, analyst targets |
| `get_obesity_drugs_early_development` | ct_gov_mcp | Next-gen competition | Oral GLP-1s, dual agonists |

### MCP Servers Utilized (6)

1. **WHO MCP** - Disease burden epidemiology
2. **Data Commons MCP** - Demographics, population, economics
3. **FDA MCP** - Drug approvals and competitive landscape
4. **CT.gov MCP** - Clinical trials pipeline
5. **SEC EDGAR MCP** - Financial performance by geography
6. **Financials MCP (Yahoo Finance)** - Stock performance and market sentiment

---

## Analytical Workflow

### Phase 1: Disease Burden Quantification

**Skills:**
- `get_disease_burden_per_capita(country="USA", disease_indicator="diabetes")`
- `search_indicators(query="diabetes prevalence", places=[list of countries])`
- `get_observations(variable_dcid="diabetes_prevalence", place_dcid="country/BRA")`

**Data Collected:**
- Diabetes prevalence by country (WHO)
- Obesity rates by country (WHO)
- Population by country (Data Commons)
- Age distribution (65+ = higher diabetes risk)
- Population growth trends

**Analysis:**
```python
# Calculate total addressable patient population
TAM = Population √ó Diabetes_Prevalence √ó Obesity_Rate √ó Target_Treatment_Rate

# Example: Brazil
TAM_Brazil = 215M √ó 8% √ó 30% √ó 15% = 776,000 eligible patients
```

**Output:** 50+ countries with quantified patient populations

---

### Phase 2: Market Economics & Ability to Pay

**Skills:**
- `search_indicators(query="GDP per capita", places=[countries])`
- `get_observations(variable_dcid="GDP_per_capita", place_dcid="country/SAU")`
- `get_company_segment_geographic_financials(company="Novo Nordisk")`

**Data Collected:**
- GDP per capita by country
- Healthcare spending per capita
- Novo Nordisk current revenue by geography
- Eli Lilly current revenue by geography
- Existing market penetration and infrastructure

**Analysis:**
```python
# Calculate revenue potential
Revenue_Potential = TAM √ó Annual_Treatment_Cost √ó Market_Share √ó Pricing_Factor

# Example: Saudi Arabia (high pricing power)
Revenue_SAU = 300K √ó $14,400 √ó 30% √ó 1.0 = $1.3B/year

# Example: Brazil (lower pricing power)
Revenue_BRA = 776K √ó $4,800 √ó 30% √ó 0.4 = $446M/year
```

**Output:** Revenue potential for 50+ countries with pricing adjustments

---

### Phase 3: Competitive Landscape

**Skills:**
- `get_glp1_diabetes_drugs()`
- `get_clinical_trials(term="GLP-1", location="Japan")`
- `get_clinical_trials(term="semaglutide OR tirzepatide")`
- `get_obesity_drugs_early_development()`

**Data Collected:**
- All approved GLP-1 drugs (Ozempic, Wegovy, Mounjaro, etc.)
- Label differences and competitive positioning
- GLP-1 trials by country (500+ trials)
- Phase distribution and timing
- Next-gen oral GLP-1s, dual/triple agonists pipeline

**Analysis:**
```python
# Competitive intensity scoring
Competitive_Score = f(
    num_trials_in_country,
    num_approvals,
    competitor_market_entry_timing,
    next_gen_pipeline_proximity
)

# Example: Japan
Japan_Competition = 15 trials + 2 approvals + oral GLP-1 in 2026 = Score: 65 (medium)

# Example: Brazil
Brazil_Competition = 3 trials + 0 approvals + oral GLP-1 in 2027 = Score: 25 (low)
```

**Output:** Competitive intensity scores (0-100) for each country

---

### Phase 4: Financial & Strategic Context

**Skills:**
- `get_pharma_company_stock_data(symbol="NVO")`  # Novo Nordisk
- `get_pharma_company_stock_data(symbol="LLY")`  # Eli Lilly
- `get_company_segment_geographic_financials(company="Novo Nordisk")`

**Data Collected:**
- Stock performance (NVO +60% YTD, LLY +55% YTD)
- Market cap and analyst targets
- Shareholder expectations
- Current R&D spending in diabetes/obesity
- Geographic revenue breakdown

**Analysis:**
```python
# Market cap impact estimation
Market_Cap_Impact = (Revenue_Potential / Total_Revenue) √ó Market_Cap √ó P/S_Multiple

# Example: Asia expansion
Asia_Revenue = $15B incremental
Novo_Market_Cap_Increase = ($15B / $50B) √ó $500B √ó 0.5 = $75B upside
```

**Output:** Shareholder value implications and strategic urgency

---

### Phase 5: Regulatory & Commercial Readiness

**Skills:**
- `get_disease_burden_per_capita(country="UAE", disease_indicator="healthcare infrastructure")`
- `search_indicators(query="healthcare spending", places=[countries])`
- `get_clinical_trials(term="GLP-1", status="recruiting")`

**Data Collected:**
- Healthcare infrastructure by country
- Endocrinologist/physician density
- Insurance coverage and reimbursement systems
- Regulatory approval timelines
- Healthcare expenditure patterns

**Analysis:**
```python
# Launch readiness scoring
Readiness_Score = f(
    regulatory_pathway_duration,
    healthcare_infrastructure_quality,
    reimbursement_likelihood,
    commercial_team_presence
)

# Example: UAE
UAE_Readiness = fast_approval + excellent_infrastructure + high_reimbursement = 90

# Example: India
India_Readiness = slow_approval + limited_infrastructure + low_reimbursement = 35
```

**Output:** Launch readiness scores (0-100) for each country

---

## Data Synthesis & Scoring

### Composite Priority Score

For each country, calculate weighted composite score:

```python
PRIORITY_SCORE = (
    0.40 √ó Revenue_Potential_Score +
    0.20 √ó (100 - Competitive_Intensity_Score) +  # Lower competition = better
    0.20 √ó Economic_Accessibility_Score +
    0.20 √ó Launch_Readiness_Score
)
```

### Example Calculations

**Japan:**
- Revenue: $4.2B ‚Üí Score: 90
- Competition: Medium (65) ‚Üí Score: 35
- Economic: High GDP, strong healthcare ‚Üí Score: 85
- Readiness: Established infrastructure ‚Üí Score: 80
- **COMPOSITE: 0.4√ó90 + 0.2√ó35 + 0.2√ó85 + 0.2√ó80 = 76**

**Saudi Arabia:**
- Revenue: $2.8B ‚Üí Score: 70
- Competition: Low (20) ‚Üí Score: 80
- Economic: Very high GDP, premium pricing ‚Üí Score: 95
- Readiness: Excellent infrastructure ‚Üí Score: 90
- **COMPOSITE: 0.4√ó70 + 0.2√ó80 + 0.2√ó95 + 0.2√ó90 = 79**

**Brazil:**
- Revenue: $3.5B (volume) ‚Üí Score: 80
- Competition: Low (25) ‚Üí Score: 75
- Economic: Moderate GDP, pricing constraints ‚Üí Score: 45
- Readiness: Growing infrastructure ‚Üí Score: 55
- **COMPOSITE: 0.4√ó80 + 0.2√ó75 + 0.2√ó45 + 0.2√ó55 = 68**

---

## Expected Output: Decision Matrix

### Board-Ready Report Structure

```markdown
# GLP-1 Geographic Expansion Priority Matrix (2025-2027)

## Executive Summary

Based on integrated analysis of disease burden (WHO), demographics (Data Commons),
competitive landscape (FDA, CT.gov), financial performance (SEC, Yahoo Finance),
we recommend prioritizing the following countries for immediate launch.

## TIER 1 - IMMEDIATE LAUNCH (2025)

| Country      | Population | Disease Burden | Revenue Potential | Competition | Priority Score |
|--------------|------------|----------------|-------------------|-------------|----------------|
| Saudi Arabia | 35M        | Very High (20%)| $2.8B            | Low         | 79             |
| Japan        | 125M       | High (12%)     | $4.2B            | Medium      | 76             |
| South Korea  | 52M        | High (14%)     | $2.1B            | Low         | 74             |
| Brazil       | 215M       | High (8%)      | $3.5B            | Low         | 68             |
| Australia    | 26M        | Medium (10%)   | $1.2B            | Low         | 66             |

**Combined Revenue Potential:** $13.8B by 2028
**Manufacturing Requirement:** 2M patient-years capacity
**Investment Required:** $500M manufacturing expansion
**Timeline:** 18-24 months to full launch

## TIER 2 - MEDIUM TERM (2026)

Mexico, Argentina, UAE, Singapore, Taiwan

## TIER 3 - LONG TERM (2027+)

India (pricing challenges), China (regulatory complexity), Southeast Asia

## NOT RECOMMENDED

Russia (sanctions), Low-income countries (pricing constraints)

## Key Strategic Insights

1. **Asia-Pacific Opportunity: $15B+ Untapped Market**
   - Aging populations driving diabetes epidemic
   - Growing middle class with ability to pay
   - Lower competition than Europe/US
   - First-mover advantage window: 2025-2027

2. **Gulf States: Quick Wins**
   - Highest diabetes prevalence globally (20%+)
   - Wealthy populations accepting premium pricing
   - Fast regulatory approvals (6-12 months)
   - Excellent healthcare infrastructure

3. **Latin America: Volume Play**
   - Massive patient populations (Brazil: 15M diabetics)
   - Lower pricing power ($200-400/month vs $1,200 US)
   - Requires tiered pricing strategy
   - Long-term growth potential

4. **Manufacturing Allocation**
   - Prioritize Tier 1 countries for 2025 capacity planning
   - Estimated capacity needed: 2M patient-years by 2026
   - Investment: $500M manufacturing expansion (Denmark + US)
   - Payback period: 2.1 years

5. **Competitive Timing**
   - Launch before oral GLP-1s arrive (2026-2027)
   - Build payer/provider relationships now
   - First-mover advantage in markets with limited GLP-1 experience

## Risk Factors

- **Pricing Pressure:** Emerging markets demand lower prices
- **Oral Competition:** Roche, Novo oral GLP-1s arriving 2026-2027
- **Supply Constraints:** Manufacturing ramp may limit launch speed
- **Regulatory Delays:** Approval timelines vary 6-24 months

## Mitigation Strategies

- **Tiered Pricing:** Premium pricing in wealthy markets, volume pricing in emerging
- **First-Mover:** Launch before oral competition arrives
- **Manufacturing Partnerships:** Asia-Pacific manufacturing partnerships
- **Regulatory Acceleration:** Leverage breakthrough therapy designations

## Financial Impact

**Expected Incremental Revenue (2025-2028):**
- 2025: $2.1B (partial year, first 2 countries)
- 2026: $6.8B (all 5 countries ramping)
- 2027: $11.2B (mature markets)
- 2028: $13.8B (full penetration)

**NPV Calculation (10% discount rate):** $8.2B
**ROI:** 28x over 5 years on $500M investment
**Payback Period:** 2.1 years

## Recommendation

**APPROVE** Tier 1 launches for Saudi Arabia, Japan, South Korea, Brazil, Australia.

- Commit $500M manufacturing capacity expansion
- Initiate regulatory filings Q1 2025
- Build commercial teams in target countries
- Establish pricing/reimbursement strategies by geography

**Board Decision:**
‚òê APPROVED - Proceed with Tier 1 launches
‚òê MODIFIED - Adjust country mix or timeline
‚òê DEFERRED - Await additional data
```

---

## Implementation Guide

### Step 1: Data Collection (Automated)

Execute skills in parallel to collect data:

```bash
# Phase 1: Disease Burden
python .claude/skills/disease-burden-per-capita/scripts/get_disease_burden_per_capita.py USA "diabetes"
# Repeat for 50 countries

# Phase 2: Demographics & Economics (Data Commons)
python -c "
from mcp.servers.datacommons_mcp import search_indicators, get_observations
# Collect population, GDP, healthcare spending for 50 countries
"

# Phase 3: Competitive Landscape
python .claude/skills/glp1-diabetes-drugs/scripts/get_glp1_diabetes_drugs.py
python .claude/skills/clinical-trials-term-phase/scripts/get_clinical_trials.py "GLP-1"

# Phase 4: Financial Context
python .claude/skills/pharma-stock-data/scripts/get_pharma_company_stock_data.py NVO
python .claude/skills/pharma-stock-data/scripts/get_pharma_company_stock_data.py LLY
python .claude/skills/company-segment-geographic-financials/scripts/get_company_segment_geographic_financials.py
```

**Estimated execution time:** < 10 minutes (parallel execution)

### Step 2: Data Synthesis (Strategic Agent)

Create new strategic agent: `glp1-geographic-expansion-analyst`

```yaml
# .claude/agents/glp1-geographic-expansion-analyst.md
---
name: glp1-geographic-expansion-analyst
description: Strategic analysis agent for GLP-1 geographic expansion prioritization
data_requirements:
  always:
    - type: disease_burden
      pattern: get_disease_burden_per_capita
    - type: demographics
      pattern: search_indicators + get_observations (Data Commons)
    - type: competitive_drugs
      pattern: get_glp1_diabetes_drugs
    - type: clinical_trials
      pattern: get_clinical_trials
    - type: company_financials
      pattern: get_company_segment_geographic_financials
    - type: stock_performance
      pattern: get_pharma_company_stock_data
---

You are a pharmaceutical strategic analyst specializing in GLP-1 drug
market expansion. Given disease burden, demographics, competition, and
financial data, provide prioritized country recommendations for launch.

Apply scoring methodology and create board-ready decision matrix.
```

### Step 3: Report Generation

Agent synthesizes data and produces:
- Priority score calculations
- Tiered country recommendations
- Revenue projections
- Risk assessment
- Board presentation deck

**Output format:** Markdown report + optional PDF export

---

## Value Proposition

### Traditional Approach (Without Platform)

- **Time:** 4-6 weeks for data collection and analysis
- **Cost:** $200K+ in consulting fees or internal resources
- **Data Sources:** Siloed, inconsistent, incomplete
- **Analysis Depth:** Shallow, descriptive only
- **Output Quality:** "Here's data" not "Do this"
- **Actionability:** Low - requires additional interpretation

### With This Platform

- **Time:** < 1 day (10 min data collection + analysis)
- **Cost:** $0 marginal cost (platform already exists)
- **Data Sources:** Integrated, authoritative (WHO, FDA, SEC, Data Commons)
- **Analysis Depth:** Deep, cross-functional integration
- **Output Quality:** Board-ready strategic recommendations
- **Actionability:** High - prescriptive decisions with ROI

### ROI Calculation

**Benefit:** $500M better decision (5% improvement on $10B expansion)
**Cost:** $200K traditional approach vs. $0 platform
**ROI:** 2,500x return

**Time Savings:** 95% faster (4-6 weeks ‚Üí 1 day)

---

## Next Steps

### To Implement This Scenario

1. **Verify Skills Availability**
   - ‚úÖ All 7 required skills exist in library
   - ‚úÖ All 6 MCP servers operational
   - ‚úÖ Skills use correct APIs (post-migration)

2. **Create Strategic Agent**
   - [ ] Write `glp1-geographic-expansion-analyst.md`
   - [ ] Define data requirements metadata
   - [ ] Implement scoring methodology
   - [ ] Add report templates

3. **Test Data Collection**
   - [ ] Execute all 7 skills for sample countries
   - [ ] Verify data quality and completeness
   - [ ] Validate cross-MCP integration

4. **Develop Synthesis Logic**
   - [ ] Implement priority scoring algorithm
   - [ ] Create revenue projection models
   - [ ] Build competitive intensity calculator
   - [ ] Add risk assessment framework

5. **Generate Demo Report**
   - [ ] Run full analysis for 20 countries
   - [ ] Produce board-ready presentation
   - [ ] Validate recommendations with domain experts

### Future Enhancements

- **Interactive Dashboard:** Tableau/PowerBI visualization of priority matrix
- **Real-Time Updates:** Auto-refresh as new trial data emerges
- **Sensitivity Analysis:** Test assumptions (pricing, penetration rates)
- **Scenario Planning:** Model different expansion strategies
- **Competitive Tracking:** Monitor competitor launches and adjust priorities

---

## Why This Matters

This scenario demonstrates that the platform isn't just a **data retrieval system** - it's a **strategic intelligence engine**.

The integration of:
- Epidemiology (WHO)
- Demographics (Data Commons)
- Competition (FDA, CT.gov)
- Economics (Data Commons, SEC)
- Market sentiment (Yahoo Finance)

...creates insights **impossible to achieve** with siloed data sources.

**This is transformative, not incremental.**

The platform enables strategic decisions that directly impact billions of dollars in shareholder value. It transforms weeks of manual analysis into minutes of automated insight generation.

**Most importantly:** It solves a problem companies are facing RIGHT NOW, with data available RIGHT NOW, producing recommendations that matter RIGHT NOW.

That's the power of intelligent multi-skill orchestration.
